158 related articles for article (PubMed ID: 36012405)
1. Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts.
Park S; Ahn S; Kim JY; Kim J; Han HJ; Hwang D; Park J; Park HS; Park S; Kim GM; Sohn J; Jeong J; Song YU; Lee H; Kim SI
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012405
[TBL] [Abstract][Full Text] [Related]
2. Machine learning models in breast cancer survival prediction.
Montazeri M; Montazeri M; Montazeri M; Beigzadeh A
Technol Health Care; 2016; 24(1):31-42. PubMed ID: 26409558
[TBL] [Abstract][Full Text] [Related]
3. Data Driven for Early Breast Cancer Staging using Integrated Mammography and Biopsy.
Yampaka T; Noolek D
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4069-4074. PubMed ID: 34967591
[TBL] [Abstract][Full Text] [Related]
4. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
Addanki S; Meas S; Sarli VN; Singh B; Lucci A
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
7. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection.
Schrauder MG; Strick R; Schulz-Wendtland R; Strissel PL; Kahmann L; Loehberg CR; Lux MP; Jud SM; Hartmann A; Hein A; Bayer CM; Bani MR; Richter S; Adamietz BR; Wenkel E; Rauh C; Beckmann MW; Fasching PA
PLoS One; 2012; 7(1):e29770. PubMed ID: 22242178
[TBL] [Abstract][Full Text] [Related]
8. Classification of Benign and Malignant Breast Masses on Mammograms for Large Datasets using Core Vector Machines.
Jebamony J; Jacob D
Curr Med Imaging; 2020; 16(6):703-710. PubMed ID: 32723242
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.
Miller E; Schwartzberg L
Curr Treat Options Oncol; 2020 Sep; 21(11):89. PubMed ID: 32875404
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation and breast cancer: A way forward (Review).
Vietri MT; D'Elia G; Benincasa G; Ferraro G; Caliendo G; Nicoletti GF; Napoli C
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34726251
[TBL] [Abstract][Full Text] [Related]
11. Machine learning for detection of lymphedema among breast cancer survivors.
Fu MR; Wang Y; Li C; Qiu Z; Axelrod D; Guth AA; Scagliola J; Conley Y; Aouizerat BE; Qiu JM; Yu G; Van Cleave JH; Haber J; Cheung YK
Mhealth; 2018; 4():17. PubMed ID: 29963562
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Breast Cancer Risk Predictive Models and Screening Strategies for Chinese Women.
Zhao Y; Xiong P; McCullough LE; Miller EE; Li H; Huang Y; Zhao M; Wang MJ; Kang M; Wang Q; Li JY
J Womens Health (Larchmt); 2017 Mar; 26(3):294-302. PubMed ID: 28263689
[TBL] [Abstract][Full Text] [Related]
13. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of Circulating miR-202 in Early-Stage Breast Cancer in South Korea.
Kim J; Park S; Hwang D; Kim SI; Lee H
Medicina (Kaunas); 2020 Jul; 56(7):. PubMed ID: 32659906
[No Abstract] [Full Text] [Related]
15. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.
Stathopoulou A; Vlachonikolis I; Mavroudis D; Perraki M; Kouroussis Ch; Apostolaki S; Malamos N; Kakolyris S; Kotsakis A; Xenidis N; Reppa D; Georgoulias V
J Clin Oncol; 2002 Aug; 20(16):3404-12. PubMed ID: 12177100
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay.
Fabisiewicz A; Kulik J; Kober P; Brewczyńska E; Pieńkowski T; Siedlecki JA
Acta Biochim Pol; 2004; 51(3):747-55. PubMed ID: 15448736
[TBL] [Abstract][Full Text] [Related]
17. Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer.
Wulf GG; Jürgens B; Liersch T; Gatzemeier W; Rauschecker H; Buske C; Hüfner M; Hiddemann W; Wörmann B
J Cancer Res Clin Oncol; 1997; 123(9):514-21. PubMed ID: 9341902
[TBL] [Abstract][Full Text] [Related]
18. Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment.
Eigeliene N; Saarenheimo J; Jekunen A
Oncology; 2019; 96(3):115-124. PubMed ID: 30654364
[TBL] [Abstract][Full Text] [Related]
19. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
20. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
